Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (September 2009)

52 slides from Auxilium Pharmaceuticals's investor presentation, Sep 9, 2009

  1. Slide 1: September 2009

    September 2009 Exhibit 99.1 (NASDAQ: AUXL)

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,

  3. Slide 3: Focused on Sustainable Long-term Growth

    Focused on Sustainable Long-term Growth XIAFLEX New Territories XIAFLEX New Indications XIAFLEX Peyronie’s XIAFLEX Dupuytren’s Testim

  4. Slide 4: 2009 Milestones Achieved

    • Completed enrollment in Peyronie’s Phase IIb (Feb. 2) • Filed BLA for Dupuytren's Contracture (Feb. 27) • Received FDA priority review (Apr. 28) and PDUFA Date (Aug. 28) • Secured $30 M Revolving Credit Line with Silicon Valley Bank (Aug. 4) • CORD I published in New England Journal of Medicine (S

  5. Slide 5: Anticipated XIAFLEX Events 2009-2010

    • FDA Arthritis Advisory Committee Meeting (September 16, 2009) • U.S. Dupuytren’s Contracture Launch (~ 60 days post-approval) • Top-line results of Peyronie's Phase IIb Study (4Q09) • Pfizer files MAA for Dupuytren’s Contracture in EU (2010) • Initiation of Peyronie's Phase III Studies (2010) Anti

  6. Slide 6: Pipeline Continues to Advance

    Pipeline Continues to Advance TESTIM ® GEL XIAFLEX™ XIAFLEX™ XIAFLEX™ Transmucosal Film AA4010 Transmucosal Film Transmucosal Film Hormone & Urology Note: Seeking partners for Transmucosal film product candidates PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuy

  7. Slide 7: Strong Strategic Partner for XIAFLEX in EU Validates Market Potential

    Strong Strategic Partner for XIAFLEX in EU Validates Market Potential • Compelling economics for Auxilium: • Up-front payment of $75 million • $150 million tied to regulatory milestones • $260 million based on sales milestones • Significant increasing tiered royalties based on sales of XIAFLEX in Pf

  8. Slide 8: XIAFLEX Driver of Long-Term Growth

    XIAFLEX Driver of Long-Term Growth XIAFLEX product and packaging have not been approved by the FDA

  9. Slide 9: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • State of the art biological manufacturing facility • Worldwide rights gener

  10. Slide 10: Dupuytren's Contracture is Debilitating for Patients

    Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery may be rese

  11. Slide 11: Current Treatment Options Require Invasive Surgery or Are Unapproved

    Current Treatment Options Require Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Non-surgical options > Splinting > Physical therapy > Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation

  12. Slide 12: XIAFLEX Offers an Improved Mechanism of Action

    XIAFLEX Offers an Improved Mechanism of Action • Clostridial collagenase is faster and more potent than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow clea

  13. Slide 13: CORD I - Largest Double-blind, Placebo-controlled Trial in Dupuytren's Contracture

    CORD I - Largest Double-blind, Placebo- controlled Trial in Dupuytren’s Contracture rd • Primary endpoint is reduction in contracture to within 0 - of normal > randomized in 2:1 ratio of active to placebo > enrolled a 2:1 ratio of MP:PIP > enrolled 1:1 ratio of less severe to more severe joints • Se

  14. Slide 14: Results Are Comparable to Surgery at the Joint Level

    Results Are Comparable to Surgery at the Joint Level Hurst et al. NEJM 2009 Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) P < 0.001 P < 0.001 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) P < 0.001 MP = metacarpophal

  15. Slide 15: Almost 100% of MP Joints and 2/3 of PIP Joints Achieved Better than 50% Improvement

    Almost 100% of MP Joints and 2/3 of PIP Joints Achieved Better than 50% Improvement Hurst et al. NEJM 2009 MP = metacarpophalangeal PIP = proximal interphalangeal 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% XIAFLEX (N=203) Placebo (N=103) Collagenase Placebo MP Joints (N=133) PIP Joints (N=70) 100%

  16. Slide 16: MP Joints Responded Better than PIP Joints

    MP Joints Responded Better than PIP Joints, but PIP Joints Were More Severe at Baseline Hurst et al. NEJM 2009 79.3% reduction in contracture for XIAFLEX patients vs. 8.6% reduction for placebo patients (p<0.001) Baseline Last XIAFLEX (All Joints) (N=203) Placebo (N=103) MP Joints (N=133) PIP Joints

  17. Slide 17: Greater Improvement in Range of Motion than Placebo

    Treatment with XIAFLEX Resulted in Greater Improvement in Range of Motion than Treatment with Placebo 36.7 vs 4 P < 0.001 36.7 43.9 80.7 49.5 45.3 Collagenase Placebo Hurst et al. NEJM 2009 ° ° ° ° ° °

  18. Slide 18: MP Joints Exhibited a Mean Improvement in Range of Motion

    MP Joints Treated with XIAFLEX Exhibited a 41 Mean Improvement in Range of Motion Baseline 30 Days After Last Injection Mean values were rounded to the nearest whole number. Hurst et al. NEJM 2009

  19. Slide 19: PIP Joints Exhibited a Mean Improvement in Range of Motion

    PIP Joints Treated with XIAFLEX Exhibited a 29 Mean Improvement in Range of Motion Baseline 30 Days After Last Injection ° Mean values were rounded to the nearest whole number. Hurst et al. NEJM 2009

  20. Slide 20: Early Intervention with XIAFLEX May Be the Most Effective Approach

    Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach MP Joints PIP Joints MP = metacarpophalangeal PIP = proximal interphalangeal 50 ° >50 ° 40 ° >40 ° Contracture at Baseline Hurst et al. NEJM 2009 88.9% (72/81) 57.7% (30/52) Less Severe More Severe 80.9% (17/21) 22.4% (11/4

  21. Slide 21: XIAFLEX Was Well-Tolerated in the CORD I Study

    XIAFLEX Was Well-Tolerated in the CORD I Study • Most adverse events were local reactions to injection or related to manipulation and rates were consistent with prior XIAFLEX trials • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a

  22. Slide 22: XIAFLEX is a Potential First-line Nonsurgical Option

    XIAFLEX is a Potential, First-line Nonsurgical Option for Patients with Dupuytren’s Contracture • Efficacy should compare favorably to surgery – Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies – Secondary endpoints support commercial uptake

  23. Slide 23: Phase III AE and SAE Rates Compare Favorably To Surgical Complications

    XIAFLEX Phase III AE and SAE Rates Compare Favorably To Surgical Complications Tendon / Ligament: Confirmed Tendon Rupture 3 0.12% Ligament Injury 1 0.04% Total Tendon / Ligament 4 0.15% Deep Vein Thrombosis 1 0.04% Dupuytren’s Disease 1 0.04% Complex Regional Pain Syndrome 1 0.04% Total 7 0.27% • C

  24. Slide 24: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture

    XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture

  25. Slide 25: XIAFLEX I.P. Position for Dupuytren's Contracture

    XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug granted on May 23, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity expected in EU for 10 years post-approval > Data protection granted for 8 years • Method of Use Patent in U.S. through 2014 • Use Patent in

  26. Slide 26: XIAFLEX Supply Chain

    XIAFLEX Supply Chain • API produced in Horsham, PA – 2 ° - 8 ° C storage expected at launch – Annual capacity at current yield should be sufficient for several years of global launch expectations – 1 manufacturing train in use and validated; capacity to expand for future demand • Fill and Lyophiliza

  27. Slide 27: Dupuytren's Contracture – an Unmet Medical Need

    Dupuytren’s Contracture –an Unmet Medical Need NEJM 2009 Hueston 1963 Skoog 1948 Mikkelsen 1976 Tubiana • Disease prevalence is estimated at 3%-6% of adult Caucasian population, or 13.5 to Million, in U.S. and EU, but occurs in all populations • Higher prevalence in patients of northern-European des

  28. Slide 28: Extensive Market Research Performed with Dupuytren's Surgeons

    Extensive Market Research Performed with Dupuytren’s Surgeons • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571 Orthopedic Surgeo

  29. Slide 29: Annually, >240,000 Dupuytren's Candidates Could Exist between U.S. & EU

    Annually, >240,000 Dupuytren’s Candidates Could Exist between U.S. & EU Source: 2006 Auxilium research and analysis

  30. Slide 30: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated

    Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence – Based on literature, ~ 13.5M to 27M patients in U.S. and EU, however only ~ 1M patients annually seeking treatment in U.S. and EU • Sustainable patient pool – New patients within an ageing population •

  31. Slide 31: Peyronie's Disease is a Devastating Disorder

    Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/ d

  32. Slide 32: Peyronie's Disease - an Unmet Medical Need

    Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith

  33. Slide 33: Current Surgical Options - Treatment of Last Resort

    Current Surgical Options- Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated to att

  34. Slide 34: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success

    Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a

  35. Slide 35: Study 1030 / Study 1035

    Study 1030 Percent of patients a-i-er Month 3 Month 6 Month 9 Study 1035 Tae : | Week6 Month3 Month6 Months a Innovations for tite”

  36. Slide 36: Peyronie's Phase IIb Study Top-line Data Expected in 4Q09

    Peyronie’s Phase IIb Study Top-line Data Expected in 4Q09 • Study designed to assess the safety and efficacy with XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – 12 U.S. sites • Patients must be able to maintain a ri

  37. Slide 37: Peyronie's Phase IIb Study Design

    Peyronie’s Phase IIb Study Design A XIAFLEX yes 45 B Placebo yes 15 C XIAFLEX no 45 D Placebo no 15 120 Arm Study Drug Plaque Modeling Targeted Number of Patients • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling.

  38. Slide 38: Peyronie's Phase IIb Trial Utilizes a Novel Patient Reported Outcome

    Peyronie’s Phase IIb Trial Utilizes a Novel Patient Reported Outcome (PRO) • Study is designed to validate Auxilium’s proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week period: – penile pain – Peyro

  39. Slide 39: Extensive Market Research Performed with Peyronie's Surgeons

    Extensive Market Research Performed with Peyronie’s Surgeons • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given fe

  40. Slide 40: Annually, 210,000 Peyronie's Candidates Could Exist between U.S. and Europe

    Annually , 210,000 Peyronie’s Candidates Could Exist between U.S. and Europe Source: 2006 Auxilium research and analysis

  41. Slide 41: XIAFLEX I.P. Position for Peyronie's Disease

    XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug granted on March 12, 1996 provides exclusivity for 7 years post-approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication • Method of Use Patent in U.S. through 2019 • Use Patent Granted in F

  42. Slide 42: Testim 1% Testosterone Gel: Near-Term Growth Driver

    Testim ® 1% Testosterone Gel: Near-Term Growth Driver

  43. Slide 43: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market

    Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad

  44. Slide 44: 447% +30%

    447% +30%

  45. Slide 45: Gels Continue to Drive Significant Growth in TRT Marketplace

    Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $200 $287 $340 $383 $449 $690 $563 $49 $59 $77 $118 $210 $302 $399 $459 $499 $568 $685 $819 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) July 2009 L12M: 26.4%

  46. Slide 46: Testim Quarterly Net Revenues and Scripts

    Testim® Quarterly Net Revenues and Scripts Continuing Track Record of Consistent Revenue Growth ($ in millions) 2Q09 Net Testim Revenues Y/Y Growth: +26.8% 2Q09 TRX Y/Y Growth: +15.7% Source: Auxilium and IMS data $42.8M $68.9M $95.7M $125.1M $72.1M

  47. Slide 47: Testim Patent Coverage

    Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan t

  48. Slide 48: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part

    FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers

  49. Slide 49: 1H '09 Financial Results and 2009 Guidance

    Revenues $73.9 $58.0 $155-165 R&D Expense $27.2 $26.6 $45-50 SG&A Expense $55.8 $43.2 $120-130 Net Loss ($26.6) ($25.2) ($50-55) Stock – Based Comp Expense $9.4 $4.9 $16-19 Cash & Cash Equivalents $80.4 1H ‘09 Financial Results and 2009 Guidance ($ Millions) 1H ’09 1H ‘08 Guidance Currently approxim

  50. Slide 50: Strategic Priorities in 2009 and 2010

    Strategic Priorities in 2009 and 2010 • Obtain approval from the FDA in Dupuytren’s Contracture; • Execute a successful launch in the U.S. for XIAFLEX in Dupuytren’s contracture approximately 60 days after our approval date; • Complete enrollment in the observational long term follow up study of Dup

  51. Slide 51: Focused on Sustainable Long-term Growth

    Focused on Sustainable Long-term Growth Testim XIAFLEX Dupuytren’s XIAFLEX Peyronie’s XIAFLEX New Indications XIAFLEX New Territories

  52. Slide 52: Auxilium Management Contact

    Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 September 2009 (NASDAQ: AUXL) [email protected] [email protected]

Auxilium Pharmaceuticals — Investor Presentation (September 2009) on 6ix